AUDENTES THERAPEUTICS, INC. (NASDAQ:BOLD) Files An 8-K Regulation FD Disclosure

AUDENTES THERAPEUTICS, INC. (NASDAQ:BOLD) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.

Story continues below

On January4, 2018, Audentes Therapeutics, Inc. (the “Company”) issued a press release attached hereto as Exhibit 99.1 announcing the results of data from the first interim analysis of ASPIRO patients, and the investor presentation attached hereto as Exhibit 99.2. ASPIRO is a multicenter, multinational, open-label, ascending dose, delayed-treatment control study to evaluate the safety and preliminary efficacy of AT132 in approximately 12 XLMTM patients less than five years of age.

The information furnished with this report, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 7.01 Financial Statements and Exhibits.

2


Audentes Therapeutics, Inc. Exhibit
EX-99.1 2 d710862dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Audentes Announces Positive Interim Data from First Dose Cohort of ASPIRO,…
To view the full exhibit click here

About AUDENTES THERAPEUTICS, INC. (NASDAQ:BOLD)

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company’s subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

An ad to help with our costs